Literature DB >> 21880850

Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.

Minetaro Arita1, Masae Iwai, Takaji Wakita, Hiroyuki Shimizu.   

Abstract

In the Global Polio Eradication Initiative, laboratory diagnosis plays a critical role by isolating and identifying poliovirus (PV) from the stool samples from acute flaccid paralysis (AFP) cases. In recent years, reestablishment of PV circulation in countries where PV was previously eliminated has occurred because of decreased herd immunity, possibly due to poor vaccination coverage. To monitor the vulnerability of countries to PV circulation, surveillance of neutralizing-antibody titers against PV in susceptible populations is essential in the end game of the polio eradication program. In this study, we have developed a PV neutralization test with type 1, 2, and 3 PV pseudoviruses to determine the neutralizing-antibody titer against PV in human serum samples. With this test, the neutralizing-antibody titer against PV could be determined within 2 days by automated interpretation of luciferase signals without using infectious PV strains. We validated the pseudovirus PV neutralization test with 131 human serum samples collected from a wide range of age groups (ages 1 to >60 years) by comparison with a conventional neutralization test. We found good correlation in the neutralizing-antibody titers determined by these tests. These results suggest that a pseudovirus PV neutralization test would serve as a safe and simple procedure for the measurement of the neutralizing-antibody titer against PV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880850      PMCID: PMC3209023          DOI: 10.1128/CVI.05225-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  19 in total

1.  Immunologic classification of poliomyelitis viruses. I. A cooperative program for the typing of one hundred strains.

Authors:  D BODIAN
Journal:  Am J Hyg       Date:  1951-09

Review 2.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication.

Authors:  Olen M Kew; Roland W Sutter; Esther M de Gourville; Walter R Dowdle; Mark A Pallansch
Journal:  Annu Rev Microbiol       Date:  2005       Impact factor: 15.500

3.  David Bodian's contribution to the development of poliovirus vaccine.

Authors:  Neal Nathanson
Journal:  Am J Epidemiol       Date:  2005-02-01       Impact factor: 4.897

4.  Assessment of efficacy of a live oral poliovirus vaccine for virulent Sabin-like poliovirus 1 strains in Japan.

Authors:  M Iwai; T Nakayama; K Matsuura; S Hasegawa; S Ando; M Obara; Y Nagai; H Yoshida; H Horie
Journal:  Acta Virol       Date:  2006       Impact factor: 1.162

Review 5.  Herd immunity: history, theory, practice.

Authors:  P E Fine
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

6.  L20B cells simplify culture of polioviruses from clinical samples.

Authors:  D J Wood; B Hull
Journal:  J Med Virol       Date:  1999-06       Impact factor: 2.327

7.  Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.

Authors:  Olen Kew; Victoria Morris-Glasgow; Mauricio Landaverde; Cara Burns; Jing Shaw; Zacarías Garib; Jean André; Elizabeth Blackman; C Jason Freeman; Jaume Jorba; Roland Sutter; Gina Tambini; Linda Venczel; Cristina Pedreira; Fernando Laender; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Harrie van Der Avoort; M Steven Oberste; David Kilpatrick; Stephen Cochi; Mark Pallansch; Ciro de Quadros
Journal:  Science       Date:  2002-03-14       Impact factor: 47.728

8.  Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.

Authors:  Soile Blomqvist; Carita Savolainen; Pia Laine; Päivi Hirttiö; Elisa Lamminsalo; Eija Penttilä; Silver Jöks; Merja Roivainen; Tapani Hovi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model.

Authors:  Minetaro Arita; Yasushi Ami; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

10.  Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein.

Authors:  Dong P Han; Hyung G Kim; Young B Kim; Leo L M Poon; Michael W Cho
Journal:  Virology       Date:  2004-08-15       Impact factor: 3.616

View more
  14 in total

1.  Poliovirus neutralization test with poliovirus pseudovirus to measure neutralizing antibody in humans.

Authors:  Subhash C Arya; Nirmala Agarwal
Journal:  Clin Vaccine Immunol       Date:  2012-03

2.  Development of poliovirus extraction method from stool extracts by using magnetic nanoparticles sensitized with soluble poliovirus receptor.

Authors:  Minetaro Arita
Journal:  J Clin Microbiol       Date:  2013-05-22       Impact factor: 5.948

Review 3.  Exosome Biogenesis, Regulation, and Function in Viral Infection.

Authors:  Marta Alenquer; Maria João Amorim
Journal:  Viruses       Date:  2015-09-17       Impact factor: 5.048

4.  Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.

Authors:  Peter F Wright; Ruth I Connor; Wendy F Wieland-Alter; Anne G Hoen; Austin W Boesch; Margaret E Ackerman; M Steven Oberste; Chris Gast; Elizabeth B Brickley; Edwin J Asturias; Ricardo Rüttimann; Ananda S Bandyopadhyay
Journal:  Lancet Infect Dis       Date:  2016-09-13       Impact factor: 25.071

5.  Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Authors:  Elizabeth B Brickley; Carolyn B Strauch; Wendy F Wieland-Alter; Ruth I Connor; Shu Lin; Joshua A Weiner; Margaret E Ackerman; Minetaro Arita; M Steven Oberste; William C Weldon; Xavier Sáez-Llorens; Ananda S Bandyopadhyay; Peter F Wright
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

6.  Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.

Authors:  Shelina Moonsamy; Melinda Suchard; Shabir A Madhi
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

7.  Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection.

Authors:  Bin Wang; Bin Wang; Peixin Liu; Tao Li; Wei Si; Jinsheng Xiu; Henggui Liu
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

8.  Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.

Authors:  Elizabeth B Brickley; Wendy Wieland-Alter; Ruth I Connor; Margaret E Ackerman; Austin W Boesch; Minetaro Arita; William C Weldon; Miguel G O'Ryan; Ananda S Bandyopadhyay; Peter F Wright
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

9.  Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden.

Authors:  Elizabeth B Brickley; Ruth I Connor; Wendy F Wieland-Alter; Marc S Collett; Marianne Hartford; Harrie Van Der Avoort; Austin W Boesch; Joshua A Weiner; Margaret E Ackerman; Mark A McKinlay; Minetaro Arita; Ananda S Bandyopadhyay; John F Modlin; Peter F Wright
Journal:  BMJ Glob Health       Date:  2019-08-28

10.  Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination.

Authors:  Susanna K Tan; Andrea C Granados; Julie Parsonnet; Charles Y Chiu; Jerome Bouquet; Yana Emmy Hoy-Schulz; Lauri Green; Scot Federman; Doug Stryke; Thomas D Haggerty; Catherine Ley; Ming-Te Yeh; Kaniz Jannat; Yvonne A Maldonado; Raul Andino
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.